A fully human anti-CD47 blocking antibody with therapeutic potential for cancer
Metrics: PDF 1964 views | HTML 1728 views | ?
Dadi Zeng1,*, Qiang Sun1,*, Ang Chen1, Jiangfeng Fan1, Xiaopeng Yang1, Lei Xu1, Peng Du1, Weiyi Qiu1, Weicai Zhang1, Shuang Wang1, Zhiwei Sun1
1Beijing Institute of Biotechnology, Fengtai District, Beijing 100071, China
*These two authors contributed equally to this work
Zhiwei Sun, email: email@example.com
Shuang Wang, email: firstname.lastname@example.org
Weicai Zhang, email: email@example.com
Keywords: CD47, anti-CD47 antibody, phagocytosis, cancer therapy, cell-in-cell
Received: March 17, 2016 Accepted: October 17, 2016 Published: November 15, 2016
CD47/SIRPα interaction serves as an immune checkpoint for macrophage-mediated phagocytosis. Mouse anti-CD47 blocking antibodies had demonstrated potent efficacy in the treatment of both leukemic and solid tumors in preclinical experimentations, and therefore had moved forward rapidly into clinical trials. However, a fully human blocking antibody, which meets clinical purpose better, has not been reported for CD47 up to date. In this study, we reported the isolation of a fully human anti-CD47 blocking antibody, ZF1, from a phage display library. ZF1 displayed high specificity and affinity for CD47 protein, which were comparable to those for humanized anti-CD47 blocking antibody B6H12. Importantly, ZF1 treatment could induce robust, or even stronger than B6H12, phagocytosis of leukemic cancer cells by macrophage in vitro, and protect BALB/c nude mice from cancer killing by engrafted leukemic cells (CCRF and U937) to a similar extent as B6H12 did. Thus, these data provide primary early pre-clinical support for the development of ZF1 as a fully human blocking antibody to treat human leukemia by targeting CD47 molecule.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.